JP2024511389A5 - - Google Patents

Info

Publication number
JP2024511389A5
JP2024511389A5 JP2023557142A JP2023557142A JP2024511389A5 JP 2024511389 A5 JP2024511389 A5 JP 2024511389A5 JP 2023557142 A JP2023557142 A JP 2023557142A JP 2023557142 A JP2023557142 A JP 2023557142A JP 2024511389 A5 JP2024511389 A5 JP 2024511389A5
Authority
JP
Japan
Prior art keywords
group
groups
pharmaceutical composition
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/081890 external-priority patent/WO2022199503A1/zh
Publication of JP2024511389A publication Critical patent/JP2024511389A/ja
Publication of JP2024511389A5 publication Critical patent/JP2024511389A5/ja
Pending legal-status Critical Current

Links

JP2023557142A 2021-03-24 2022-03-21 キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法 Pending JP2024511389A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110316525 2021-03-24
CN202110316525.6 2021-03-24
CN2022074619 2022-01-28
CN202210109766 2022-01-28
CNPCT/CN2022/074619 2022-01-28
CN202210109766.8 2022-01-28
PCT/CN2022/081890 WO2022199503A1 (zh) 2021-03-24 2022-03-21 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Publications (2)

Publication Number Publication Date
JP2024511389A JP2024511389A (ja) 2024-03-13
JP2024511389A5 true JP2024511389A5 (https=) 2025-03-25

Family

ID=83396096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557142A Pending JP2024511389A (ja) 2021-03-24 2022-03-21 キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法

Country Status (7)

Country Link
US (1) US20250268897A1 (https=)
EP (1) EP4316490A4 (https=)
JP (1) JP2024511389A (https=)
KR (1) KR20230159367A (https=)
CN (1) CN116801882A (https=)
AU (1) AU2022242476A1 (https=)
WO (1) WO2022199503A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022022398A1 (zh) * 2020-07-28 2022-02-03 四川科伦博泰生物医药股份有限公司 一种嘧啶类化合物的盐和晶型及其制备方法
CN120897743A (zh) 2023-05-19 2025-11-04 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与ret基因改变相关疾病的用途和方法
WO2026017002A1 (zh) * 2024-07-16 2026-01-22 四川科伦博泰生物医药股份有限公司 以杂环化合物为活性成分的药物组合物、其制备方法及用途
GB202410599D0 (en) 2024-07-19 2024-09-04 Ellipses Pharma Ltd Therapeutics useful synergistic combinations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145391B2 (en) * 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
US10227329B2 (en) * 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
JP7615056B2 (ja) 2019-02-19 2025-01-16 スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド 複素環化合物、これを含む薬物組成物、その製造方法および使用
EA202193049A1 (ru) * 2019-05-21 2022-02-14 Вороной Инк. N-содержащее производное гетероарила и фармацевтическая композиция, содержащая его в качестве активного ингредиента для предупреждения или лечения рака
JP7732668B2 (ja) * 2019-08-05 2025-09-02 北京志健金瑞生物医▲薬▼科技有限公司 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途

Similar Documents

Publication Publication Date Title
JP2024511389A5 (https=)
JPWO2022138987A5 (https=)
CN111065639B (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
AU2007336781C1 (en) Pyridazinones and furan-containing compounds
US6734203B2 (en) Fused imidazolium derivatives
IL268030B2 (en) Bicyclics as allosteric shp2 inhibitors
JP2022520448A5 (https=)
CN110582483A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JP2018520205A (ja) レンバチニブメシル酸塩の新規結晶形及びその製造方法
AU2016327857B2 (en) EGFR kinase inhibitor and preparation method and use thereof
WO2019012172A1 (es) Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2)
JP2023526791A5 (https=)
JP2018529690A5 (https=)
WO2021016333A1 (en) Aryl sulfonamides as small molecule stat3 inhibitors
CN107698603A (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
WO2022166592A1 (zh) 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
JP2025120182A5 (https=)
JP2018529643A5 (https=)
CN109790145A (zh) 二氢嘧啶类化合物及其制备方法和用途
US9738613B2 (en) Substituted 1,2,3-triazoles as antitumor agents
CN112174950A (zh) 杂环衍生物、包含其的药物组合物及其用途
JPWO2021117759A5 (https=)
CN111295387B (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
CN111718349A (zh) 含氟吡唑并嘧啶化合物和药物组合物及其应用
EP3628374B1 (en) Bcl-3 inhibitors